FierceBiotech22d
Eisai, Eli Lilly didn't disclose heightened brain injury risk to Alzheimer's trial patients: NYT
According to a New York Times report this week, Eisai and Eli Lilly, in the clinical trials for their respective Alzheimer’s drugs Leqembi and Kisunla, genetically tested participants to ...
Kellogg School of Management10y
Haruo Naito gives back with a world of insight
As president and CEO of the Japanese human healthcare company Eisai Co. Ltd., he assumed the leadership of ... and the gastric disorder medication, Aciphex/Pariet. "The dynamics and excitement are the ...
Reuters16d
Eisai Co Ltd
Future of Healthcategory Benefit of Eisai and Biogen's Alzheimer's drug increases over time, studies suggest July 30, 2024 Businesscategory Shares of Japan's Eisai tumble after EU rejects ...
Morningstar7d
Eisai updates Leqembi® outlook for fiscal year 2024 (April 2024 - March 2025). Sales now expected to reach JPY 42.5 billion
STOCKHOLM, Nov. 7, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today updated their revenue outlook for Leqembi for their 2024 fiscal year (FY), which runs ...
Nature3y
Modifying the course of Alzheimer’s disease: Biogen and Eisai perspectives
Bruce Albala works at Eisai, Inc., 100 Tice Boulevard, Woodcliff Lake, New Jersey 07677, United States. Samantha Budd Haeberlein Samantha Budd Haeberlein works at Biogen, 225 Binney Street ...